Integrum Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Scott Flora

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Scott Flora (68 yo)

less than a year

Mandato

Mr. Scott D. Flora is the Acting CEO since September 15, 2024 and serves as Director from September 27, 2023 and he previously served as Adjunct Board Member of Integrum AB (publ) since May 11, 2023 until...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Rickard Branemark	Founder	2.5yrs	SEK 3.40m	Nessun dato
Scott Flora	Acting CEO & Director	less than a year	Nessun dato	Nessun dato
Jorgen Svanstrom	Interim Chief Finance Officer	1.5yrs	Nessun dato	Nessun dato
Inger Rydin	Chief Operating Officer	less than a year	Nessun dato	Nessun dato
Karin Ganlöv	Chief Medical Officer	2.5yrs	Nessun dato	Nessun dato
Jeffrey Zanni	President of U.S. & Head of American Operations	1.3yrs	Nessun dato	Nessun dato
Jerry Frimanson	Head of Supply	less than a year	Nessun dato	Nessun dato
Anna-Tove Branemark	Chief Executive Officer of Integrum Inc.	no data	Nessun dato	Nessun dato

1.3yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di 6Y1 non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rickard Branemark	Founder	no data	SEK 3.40m	Nessun dato
Scott Flora	Acting CEO & Director	1.2yrs	Nessun dato	Nessun dato
Bengt Sjoholm	Chairman	5yrs	SEK 100.00k	Nessun dato
Karin Wingstrand	Director	no data	SEK 100.00k	Nessun dato
Andrew Christensen	Director	no data	SEK 100.00k	Nessun dato
Patric Lindgren	Independent Director	4.8yrs	SEK 376.29k	Nessun dato
Cecilia Wikstrom	Independent Director	4.8yrs	SEK 100.00k	Nessun dato

4.8yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6Y1 sono considerati esperti (durata media dell'incarico 4.8 anni).

Integrum Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum AB (Publ) Announces Management Changes

Recent updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

New minor risk - Shareholder dilution

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

New major risk - Share price stability

Full year 2023 earnings released

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q1, 2023 Results on Sep 02, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant System

Third quarter 2021 earnings released

BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant System

Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the US

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media